Berkshire Health Systems
  • Coronavirus Information Kiosk
  • Berkshire Patient Portal
  • COVID-19 Relief Fund for Berkshire Health Systems
  • Pay Your Bill Online
  • About Us
  • Employment
  • Medical Staff Portal
  • Coronavirus Information Kiosk
  • Berkshire Patient Portal
  • BMC Parking Maps
  • Advocacy for Access
  • Berkshire Patient Portal
  • BHS Blood Drawing Stations
  • BHS Bloodmobile
  • BHS Community Benefits Implementation Plan
  • BHS News
  • BHS Privacy Practices
  • BMC Community Benefits Report FY 2018
  • Fairview Hospital FY 2018 Community Benefit Report
  • BMC Medical Interpreters
  • Community Outreach Program
  • County Health Needs Assessment
  • Financial Counseling/Ayuda Financiera
  • Helpful Patient Tools
  • Medical Interpreters at Fairview
  • MedlinePlus
  • MedlinePlus en Espanol
  • One Medical Passport
  • Pay Your Bill Online
  • Pre-Surgical Assessment
  • Request a Medical Record
  • Send a Patient Greeting
  • Wellness Works Website - For BHS Employees & Spouses
  • Worksite Wellness
Berkshire Health Systems
  • Programs & Services
    • Addiction Services
    • Anesthesiology
    • Bariatrics
    • Better Start
    • Cancer Care
    • Cardiology
    • Concussion
    • Diabetes Care
    • Emergency Care
    • Endoscopy
    • Healthy Steps
    • Home Care
    • Hospitalists
    • Kidney & Dialysis
    • Laboratory Services
    • Maternity
    • Neurology
    • Neurosurgery
    • Occupational Med
    • Orthopedics
    • Outreach
    • Pain Management
    • Pharmacy
    • Psychiatry
    • Pulmonary Care
    • Radiology
    • Rehabilitation
    • Sleep Disorders
    • Sports Medicine
    • Stroke Care
    • Surgery
    • Trauma Care
    • Travel Medicine
    • Urgent Care
    • Urology
    • Wellness
    • WIC Program
    • Women's Imaging
    • Wound Care
    • Patient & Visitor Information
    • Quality Care & Patient Safety
    • Calendar & Events
    • News
    • Maps & Directions
    • Ways to Give
    • Health Encyclopedia
    • Berkshire Medical Center, Pittsfield, MA
    • Fairview Hospital, Great Barrington, MA
    • Berkshire Visiting Nurse Association
    • BHS Survey Module
  • Locations
    • Berkshire Medical Center
    • Fairview Hospital
    • North Adams Campus of BMC
    • BMC & Fairview Physician Practices
    • Berkshire Visiting Nurse Association
    • BHS Urgent Care
    • Long Term Care
    • BHS Laboratory - Blood Drawing Stations
  • Find a Physician
  • BHS Physician Practices
  • Medical Education
    • Message from Dr. Alex Sabo
    • Internal Medicine Residency
    • Surgery Residency
    • Osteopathic Medical Education
    • Psychiatry Residency
    • Dentistry Residency
    • Medical Students
    • Continuing Medical Education
    • School of Medical Technology
    • Schwartz Center Rounds
  • Coronavirus Information Kiosk
  • Berkshire Patient Portal
  • COVID-19 Relief Fund for Berkshire Health Systems
  • Pay Your Bill Online
  • About Us
  • Employment
  • Medical Staff Portal
RTOG 0815- A Phase III Prospective Randomized Trial of Dose-escalated Radiotherapy With or Without Short-Term and Androgen Deprivation Therapy for Patients With Intermediate-Risk Prostate Cancer
  1. Home
  2. Clinical Trials

Clinical Trials

Principal Name   Harvey Zimbler, MD
Contact Name   Gloria Gero
Phone   (413) 496-8205
Alternate Phone   (413) 443-6000
Fax   (413) 443-2203
Title   RTOG 0815- A Phase III Prospective Randomized Trial of Dose-escalated Radiotherapy With or Without Short-Term and Androgen Deprivation Therapy for Patients With Intermediate-Risk Prostate Cancer"
Description   Primary objective;
to demonstrate an oveall survival (OS) advantage for the addition of short-term (6 months) ADT to dose-escalated RT for patients with intermediate-risk prostate cancer. The events for OS will be defined as death due to any cause.
Secondary objective :
- Determine whether the addition of ADT to dose-escalated RT imporves clinical failures (local recurrence, regional recurrence, or distant metastasis), biochemical failure by the "nadir + 2" (Phoenix) definition, freedom from failure (the first occurrence of clinical failure or biochemical falure by the Phoenix definition), rate of salvage ADT, and prostate cancer-specific mortality without resulting in increased non-prostate cancer-specific mortality over dose-escalated RT alone.
- Estimate the magnitude of benefit of ADT with respect to OS for patients treated with different RT modalities
- Compare acute and late treatment adverse events for patients receviing vs. not receiving ADT and correlate this
with the presence or absence of pre-existing comorbidity as documented by the Adult Comorbity Evaluation 27
assessment
- Determien whether HRQOL as measured by the EPIC significantly worsens as a funciton of treatment assignment.
- Demonstrate the addition of ADT to dose-escalated RT is associated with the higher fatigue severity than dose-
escalated RT alone by the Patient-Reporeted Outscome Measurement Inforatino System (PROMIS) fatigue domain
Treatment   Oncology
Inclusion/Notes   ELIGIBILITY- - Pathologically (histologically)proven diagnosis of prostatic adenocarcinoma, at intermediate risk for recurrence, within 6 months prior to registration as determined by having onr or more of the following intermediate-risk features: Gleason Score 7; PSA>10 but <20; Clnical Stage T2b-T2c. - Patients preiously diagnosed with low risk (Gleaseon score <6, clinical stage 18 - Baseline serum PSA performed with an FDA-approved assay within 60 days prior to registration - For patients undergoing brachytherapy only: CBC/differential obtained within 60 days prior to registration, with adequate bone marrow function defined as follows: ANC > 1800 cell/mm3 Platelets >100,000 cell/mm3 Hemoglovin >8.0 g/dl - Patient must be able to provide study-specific informed consent prior to study entry. INELIGIBILITY: - Patients with GLeason score >8; PSA>20 OR Clnical Stage > T3 are ineligible for this trial - Patient with all three intermediate risk factors who also have >50% of the nuber of their biopsy cores positive for cancer - Prior invasive malignancy or hematological mealignancy unless disease free for a minimun of 5 years - Prior radical surgery (prostatectomy), high-intensity focused ultrasound or cryosurgery for prostate cancer. - Prior hormonal therapy, such as LHRH agonists, estrogens,l or bilateral orchiectomy - Use of finasteride within 30 days prior to registration - Use of dutasteride within 90 days prior to registration - Prior RT, including bracytherapy, to the region of the study cancer that would result in overlap of RT fiels. - Severe active co-morbibity - Men who are sexually active with a woman ofchild-bearing portential and not willing/able to use medically acceptable forms of contraception during protocol treatment and during the first 3 months after cessation of protocol treatment.
Status   accruing
Current Trial Type   Treatment
  •   (413) 447-2000
  •   Email - General Inquiries Only
  •   Email - BMC Patient Experience
  •   Email - BHS Physician Practices
  •   Email - Fairview Hospital Inquiries
  • Employment at BHS
  • About Us
  • 2018 BMC Report on Cancer
  • Quality Care & Patient Safety
  • Berkshire Patient Portal
  • Awards & Accreditations
  • BHS Community Outreach
  • BHS Bloodmobile
  • BMC FY 2018 Community Benefits Report
  • Fairview FY 2018 Community Benefits Report
  • Ways to Give
  • Give Us Your Feedback

© 2021 Berkshire Health Systems

725 North Street

Pittsfield, MA 01201

  • News
  • Privacy Practices
  • Practicas De Privacidad
  • Site Map
  • BHS Privacy Practices
  • Contact Us